A Novel Approach to Type 1 Diabetes ManagementThis ground-breaking research study reveals pledge as the very first disease-modifying treatment of its kind for type 1 diabetes that can be delivered as a tablet. The Burden of Type 1 Diabetes and Potential for ChangeUp until insulins discovery more than 100 years ago, type 1 diabetes was a deadly condition. Recommendation: “Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes” by Michaela Waibel, John M. Wentworth, Michelle So, Jennifer J. Couper, Fergus J. Cameron, Richard J. MacIsaac, Gabby Atlas, Alexandra Gorelik, Sara Litwak, Laura Sanz-Villanueva, Prerak Trivedi, Simi Ahmed, Francis J. Martin, Madeleine E. Doyle, Jessica E. Harbison, Candice Hall, Balasubramanian Krishnamurthy, Peter G. Colman, Leonard C. Harrison, Helen E. Thomas and Thomas W.H. Kay, 5 December 2023, New England Journal of Medicine.DOI: 10.1056/ NEJMoa2306691The scientific trial was funded by JDRF, the leading type 1 diabetes neighborhood, advocacy, and research programs company, consisting of through the JDRF Type 1 Diabetes Clinical Research Network.
A Novel Approach to Type 1 Diabetes ManagementThis ground-breaking research reveals guarantee as the very first disease-modifying treatment of its kind for type 1 diabetes that can be delivered as a tablet. The Burden of Type 1 Diabetes and Potential for ChangeUp up until insulins discovery more than 100 years ago, type 1 diabetes was a fatal condition. Reference: “Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes” by Michaela Waibel, John M. Wentworth, Michelle So, Jennifer J. Couper, Fergus J. Cameron, Richard J. MacIsaac, Gabby Atlas, Alexandra Gorelik, Sara Litwak, Laura Sanz-Villanueva, Prerak Trivedi, Simi Ahmed, Francis J. Martin, Madeleine E. Doyle, Jessica E. Harbison, Candice Hall, Balasubramanian Krishnamurthy, Peter G. Colman, Leonard C. Harrison, Helen E. Thomas and Thomas W.H. Kay, 5 December 2023, New England Journal of Medicine.DOI: 10.1056/ NEJMoa2306691The scientific trial was funded by JDRF, the leading type 1 diabetes neighborhood, research, and advocacy programs organization, including through the JDRF Type 1 Diabetes Clinical Research Network.